Skip to main
INGN
INGN logo

Inogen (INGN) Stock Forecast & Price Target

Inogen (INGN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Inogen Inc is strategically positioned for growth through its focus on enhancing synergies across sales channels and revitalizing its direct-to-consumer business, which could strengthen its competitive advantage in the portable oxygen concentrator market. The partnership with Yuwell for entry into the Chinese market presents significant long-term growth potential, capitalizing on a COPD market that is approximately ten times larger than that of the United States. Additionally, the projected growth of portable oxygen concentrators to comprise 58% of the market over the next five years further underscores the favorable outlook for Inogen's product demand.

Bears say

Inogen Inc. is facing significant challenges due to an oversized sales force that previously resulted in unprofitable operations, despite revenue growth. The company experienced marked revenue declines in both business-to-business (17%) and direct-to-consumer (28%) sales in 2023, indicating difficulties in its sales channel optimization efforts following new leadership in 4Q23. Additionally, shifts in patient reimbursement sources from higher-paying Medicare to lower-reimbursing private insurance and an increasing number of capped patients have further exacerbated revenue challenges, raising concerns about future financial stability.

Inogen (INGN) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inogen (INGN) Forecast

Analysts have given Inogen (INGN) a Buy based on their latest research and market trends.

According to 3 analysts, Inogen (INGN) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inogen (INGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.